01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – Notice of Trading Update July 9, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30 June 2025 on Tuesday 22 July 2025.   Investor presentation   Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the trading update via the Investor Meet Company platform on Tuesday 22 July 2025…

Continue reading

#HVO hVIVO PLC – Notice of Results March 21, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces that it will release its final results for the year ended 31 December 2024 on Thursday 10 April 2025.   Analyst briefing   A briefing open to equity research analysts will take place on Thursday 10 April 2025 at 11.00am BST. To register and for more details please contact Walbrook PR on hvivo@walbrookpr.com.  …

Continue reading

#HVO hVIVO PLC – Positive results from RSV human challenge trial October 7, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Enanta Pharmaceuticals (“Enanta”), reporting positive topline results from a Phase 2a Respiratory Syncytial Virus (“RSV”) human challenge trial (“HCT”) in healthy adults conducted by hVIVO for EDP-323, its second RSV antiviral candidate.   EDP-323, a novel, oral, direct-acting antiviral in development for RSV infection, has…

Continue reading

#HVO hVIVO PLC – Notice of Results March 27, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its full year results for the twelve months ended 31 December 2023 on Tuesday 9 April 2024.   Analyst briefing   A briefing open to equity research analysts will take place on Tuesday 9 April 2024 at 12.00 pm BST. To…

Continue reading

#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)

£16.8m full-service RSV contract with top five global pharma client Highlights ·    Pharma client is funding expedited manufacture of additional supply of RSV challenge agent ·    Confirmatory challenge cohort to verify infectivity of the new RSV challenge virus batch ·    Multiple cohort challenge trial to test efficacy of client’s RSV antiviral candidate ·    Trading ahead of previous market expectations driven by margin expansion   hVIVO plc (AIM & Euronext: HVO), the world leader in testing…

Continue reading

#HVO hVIVO PLC – Presentation at World Vaccine Congress March 29, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below:   Title Challenge Studies – can the results be expected to mimic…

Continue reading

#HVO hVIVO PLC – £6.8m RSV human challenge contract signed February 6, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.8m contract with a leading pharmaceutical company based in Asia Pacific (“APAC”), to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model.                                 The Phase 2a double-blinded placebo-controlled…

Continue reading